Full Press Release Details
Medical to Open Inaugural
Endovascular Robotics Session at the
Society of Robotic Surgery Annual Meeting
Endovascular Innovators to Highlight Emergence and Growth of
Robotics in the Specialty
Mass., July 8, 2025 -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic
System, announced its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting,
being held from July 16-20, in Strasbourg, France. The Company applauds the SRS for recognizing the growing need to spotlight this field,
which Microbot believes is being driven by rapid innovation and rising market demand.
panel session, titled: Endovascular Robotics; the next frontier for robotic surgery, will take place at 1:30am CEST on Saturday
July 19th and will be moderated by Dr. Adnan Siddiqui, a University of Buffalo Distinguished Professor and Vice Chairman in the Department
of Neurosurgery (UBNS) at the State University of New York at Buffalo's Jacobs School of Medicine and Biomedical Sciences, and
Dr. Ryan Madder, Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health in Grand Rapids,
Gadot, the Company's Chairman, CEO and President, will present an overview of the endovascular robotic market. Mr. Gadot will
be joined by representatives from other medical robotics companies to discuss emerging technologies in the peripheral vascular, neurovascular
and cardiovascular spaces. The SRS meeting provides the Company a timely platform to introduce and educate Interventional Radiologists
(IR) and the broader medical community on the LIBERTY system.
SRS is founded on the fundamental principles of education and collaboration as a means to tackle the complex issues of robotic surgery.
SRS provides possibilities in terms of multi-centric studies, database collection, fellowship training and funding support. The organization
seeks participation from residents and fellows and young faculty in the hope that they can assist them as they embrace robotics. The
society is global with each continent having its own board and input into SRS activities.
Company is strengthening its sales and marketing infrastructure as part of the LIBERTY launch plans in the United States, while awaiting
the anticipated U.S. Food and Drug Administration's (FDA) 510(k) decision during the current quarter.
an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S.
Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics
and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use,
fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
information about Microbot Medical is available at http://www.microbotmedical.com.
to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements
that contain words such as "contemplates," "continues," "could," "forecasts," "intends,"
"may," "might," "possible," "potential," "predicts," "projects,"
"should," "would," "will," "believes," "plans," "anticipates,"
"expects," "estimates" and similar expressions) should also be considered to be forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,
including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition
to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular
Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant
510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting
from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements
of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran
and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical
can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and
Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking statements, except as required by law.